BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND ECT2L, 345930, C6orf91, Q008S8, LFDH, dJ509I19_3, dJ509I19_2, ENSG00000203734
109642 results:

  • 1. Risk factor analysis and nomogram development and verification for medullary carcinoma of the colon using SEER database.
    Yang L; Yu L; Zhou Q; Liu L; Shen N; Li N
    Sci Rep; 2024 May; 14(1):11426. PubMed ID: 38763982
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Squalene epoxidase promotes the chemoresistance of colorectal cancer via (S)-2,3-epoxysqualene-activated NF-κB.
    Liu Q; Zhang Y; Li H; Gao H; Zhou Y; Luo D; Shan Z; Yang Y; Weng J; Li Q; Yang W; Li X
    Cell Commun Signal; 2024 May; 22(1):278. PubMed ID: 38762737
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Potential drug targets for tumors identified through Mendelian randomization analysis.
    Song N; Shi P; Cui K; Zeng L; Wang Z; Di W; Li J; Fan Y; Li Z; Zhang J; Su W; Wang H
    Sci Rep; 2024 May; 14(1):11370. PubMed ID: 38762700
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Construction of a nomogram based on clinicopathologic features to predict the likelihood of No. 253 lymph node metastasis in rectal cancer patients.
    Chen W; Cai Z; Zhou J; Xu Z; Li Z; Guo Z; Li J; Guo Z; Wu H; Xu Y
    Langenbecks Arch Surg; 2024 May; 409(1):161. PubMed ID: 38761214
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The role of preoperative FPR and FAR in prognostic evaluation of stages II and III radical colorectal cancer: A single-center retrospective study.
    Yan H; Liu T; Yu R; Xia D
    Medicine (Baltimore); 2024 May; 103(20):e38145. PubMed ID: 38758911
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Exploring Guolin Qigong (Mind-Body Exercise) for Improving cancer Related Fatigue in cancer Survivors: A Mixed Method Randomized Controlled Trial Protocol.
    Low SLK; Ho GF; Liu B; Koh ES; Fei Y; Teo CS; Zhu X
    Integr Cancer Ther; 2024; 23():15347354241252698. PubMed ID: 38757745
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Superficial fibromas with CTNNB1 mutation.
    Kuntze A; Meliß RR; Ermert L; Falkenberg KD; Puller AC; Trautmann M; Hartmann W; Wardelmann E
    Genes Chromosomes Cancer; 2024 May; 63(5):e23247. PubMed ID: 38757718
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Daunorubicin induces GLI1‑dependent apoptosis in colorectal cancer cell lines.
    Kim BR; Kim DY; Tran NL; Kim BG; Lee SI; Kang SH; Min BY; Hur W; Oh SC
    Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757343
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Serrated polyposis syndrome: defining the epidemiology and predicting the risk of dysplasia.
    Dierick NR; Nicholson BD; Fanshawe TR; Sundaralingam P; Kostalas SN
    BMC Gastroenterol; 2024 May; 24(1):167. PubMed ID: 38755550
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Upregulation of Immune checkpoint PD-L1 in Colon cancer cell lines and activation of T cells by Leuconostoc mesenteroides.
    Altves S; Guclu E; Yetisgin E; Bilecen K; Vural H
    World J Microbiol Biotechnol; 2024 May; 40(7):204. PubMed ID: 38755413
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. When to reinvite initially ineligible populations for targeted lung cancer screening?
    Goodley P; Crosbie PAJ; Sperrin M; Merchant Z; Booton R; Balata H
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38754907
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
    Salim N; Tumanova K; Popodko A; Libson E
    JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Clinicopathologic Profile and Treatment Outcomes of colorectal cancer in Young Adults: A Multicenter Study From India.
    Sehrawat A; Khanna M; Kayal S; Sundriyal D; Tiwari S; Cyriac S; Ravishankaran P; Raphael J; Mathew D; Panda SS; Moharana L; Mohanty SS; Mohanty SS; Philips A; Jain D; Jeyaraj P; David PH; Patil J; Saju SV; Rathnam K; Sharma N; Dheva K; Jinkala SR; Raja K; Penumadu P; Ganesan P
    JCO Glob Oncol; 2024 May; 10():e2300225. PubMed ID: 38754051
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Determinants and Factors of Physical Activity After Oncology Treatments (DEFACTO) in Metropolitan France: Protocol of a Mixed Methods Study and Intervention.
    Aumaitre A; Gagnayre R; Foucaut AM
    JMIR Res Protoc; 2024 May; 13():e52274. PubMed ID: 38753415
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Value of Real-World Evidence for Treatment Selection: A Case Study in Colon cancer.
    Shen L; van Gestel A; Prinsen P; Vink G; van Erning FN; Geleijnse G; Kaptein M
    JCO Clin Cancer Inform; 2024 May; 8():e2300186. PubMed ID: 38753347
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Small Nucleolar RNAs as Diagnostic and Prognostic Biomarkers in cancer: A Systematic Review and Meta-Analysis.
    Gao L; Fan J; He J; Che X; Wang X; Han C
    Technol Cancer Res Treat; 2024; 23():15330338241245939. PubMed ID: 38752263
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. CircAGFG1 Promotes Ovarian cancer Progression Through the miR-409-3 p/ZEB1 Axis.
    Luo J; Zhong H; Guo M; Xiao P; Cao R; Zhao M; Jing Y
    Technol Cancer Res Treat; 2024; 23():15330338241252423. PubMed ID: 38752261
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Understanding the interplay of colorectal cancer awareness and attitudes among Palestinians: a national cross-sectional study.
    Elshami M; Dwikat MF; Al-Slaibi I; Alser M; Albandak ME; Ayyad M; Naji SA; Mohamad BM; Isleem WS; Shurrab A; Yaghi B; Qabaja YA; Hamdan FK; Sweity RR; Jneed RT; Assaf KA; Hmaid MM; Awwad II; Alhabil BK; Alarda MN; Alsattari AS; Aboyousef MS; Aljbour OA; AlSharif R; Giacaman CT; Alnaga AY; Nemer RMA; Almadhoun NM; Skaik SM; Albarqi SI; Abu-El-Noor N; Bottcher B
    BMC Cancer; 2024 May; 24(1):590. PubMed ID: 38750448
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Effect of GP visits in the compliance of preventive services: a cross-sectional study in Europe.
    Ares-Blanco S; López-Rodríguez JA; Polentinos-Castro E; Del Cura-González I
    BMC Prim Care; 2024 May; 25(1):165. PubMed ID: 38750446
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.
    Segal NH; Melero I; Moreno V; Steeghs N; Marabelle A; Rohrberg K; Rodriguez-Ruiz ME; Eder JP; Eng C; Manji GA; Waterkamp D; Leutgeb B; Bouseida S; Flinn N; Das Thakur M; Elze MC; Koeppen H; Jamois C; Martin-Facklam M; Lieu CH; Calvo E; Paz-Ares L; Tabernero J; Argilés G
    Nat Commun; 2024 May; 15(1):4091. PubMed ID: 38750034
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5483.